Nearly 6.7 million adults in the U.S. have heart failure, with prevalence expected to rise to 8.5 million by 20301,2. While heart failure is a chronic, progressive disease, advances in technology are ...

St. Jude Medical’s CardioMEMS HF System demonstrates our commitment to delivering high-quality, innovative solutions that reduce health care costs and improve outcomes for patients ST. PAUL, Minn.-- ...

The CardioMEMS HF System is proven to significantly reduce heart failure hospitalizations and improve quality of life in NYHA class III HF patients St. Jude Medical now intends to exercise its ...

ST. PAUL, Minn. -- St. Jude Medical, Inc., a global medical device company, today announced a new data analysis from the CHAMPION clinical trial that evaluated outcomes in a subgroup of patients with ...

The US Food and Drug Administration (FDA) has expanded the indication for Abbott's CardioMEMS heart failure (HF) system, making an additional 1.2 million patients in the United States eligible for the ...

(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved an expanded indication for the company's CardioMEMS HF System to support the care of more people living with heart ...

Abbott Laboratories ABT recently gained FDA approval of an expanded indication for its CardioMEMS HF System to support the care of heart failure patients. The CardioMEMS HF System has been found to ...

WASHINGTON (Reuters) - A Food and Drug Administration review of CardioMEMS' device for treating heart failure found it has met its main safety and effectiveness goals, based on trial results. But the ...

ATLANTA, Aug. 26 -- CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today ...

A local Medicare contractor issues a final ruling declining to cover CardioMEMS, the wireless, implantable heart failure management device from St. Jude Medical. Arundhati Parmar St. Jude Medical has ...

NEW ORLEANS – The sponsors of the Cardiomems heart failure monitoring system have struggled to gain acceptance from public payers, but data from a U.S. FDA-mandated post-approval study show that the ...